InvestorsHub Logo
Followers 22
Posts 587
Boards Moderated 0
Alias Born 08/19/2020

Re: None

Saturday, 08/22/2020 1:36:27 PM

Saturday, August 22, 2020 1:36:27 PM

Post# of 44690
I have compiled a list of facts. Please let me know if I missed anything!

Aviptadil RLF-100 VIP

• Aviptadil is a repurposed erectile dysfunction drug, proven to be safe since 1970’s.
• Aviptadil blocks Covid from attaching to host cells in the lungs, prevents the cytokine storm, and reduces inflammation. This is a targeted trifecta for treating Covid.
• An inhaler version of Aviptadil will undergo clinical trials, with the intent to ultimately be used for in-home treatment of Covid cases. This study is expected to complete around Nov 31, with results being published sometime afterwards.
• Aviptadil is inexpensive and easy to manufacture.
• Aviptadil shows promise for other lung applications beyond Covid, which also needs to be studied and tested.

Stock/Company

• Relief Therapeutics holds the patent on Aviptadil. It is a small company in Switzerland, traded over the counter (OTC).
• NeuroRX is a private US-based partner with leadership that is well-connected at the highest levels of government and big pharma. They are guiding Relief Therapeutics through the FDA approval process.
• Company has $3M cash, but will need approx. another $20M to complete all 3 trials, including inhaler version.
• Unconfirmed: Most of the outstanding shares are owned by insiders.
• Chairman Raghuram (Ram) Selvaraju says there is no real need to raise capital via additional shares at this point, due to liquidity option provided by GEM.
• Speculation: Company may have recently raised enough additional capital to complete trials through Princeton Angels.

Manufacturing and Distribution

• Robert Bestoff, Chief of Operations, spent his career at Lilly & Pfizer. At Pfizer, he was head of entire neuro science and pain division and was responsible for $10b of drugs.
• Manufacturing program put together by Rich Siegel, former head of Johnson & Johnson’s drug portfolio.
• 2 Partnership arrangements are expected to be announced soon.
• “We are about to announce a partnership with the largest supplier of inhaled sterile drugs in the United States.” NeuroRX CEO Dr. Javitt
• “We are about to announce a partnership with a very large well-known public company that can get any drug to any hospital overnight” NeuroRX CEO Dr. Javitt
• “By October, we should be manufacturing enough drug for 100,000 people each month.” NeuroRX CEO Dr. Javitt